Expression of Ion Channels During Ganglion Cell Apoptosis—Implications for the Pathogenesis of Glaucomatous Optic Neuropathy and Relevance for Neuroprotective Treatment

About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - May 31, 2011
Grant ID
G2008010
Goals
This study investigates the ability of an epilepsy drug to reduce cell death related to glaucoma.
Summary
Loss of vision in glaucoma patients is caused by death of ganglion cells in the retina. Therefore, preventing the death of these cells may preserve vision. To develop a drug to prevent cell death there must be an understanding of this process. The researchers believe that changes in electrical currents may be the ‘trigger’ that leads to cell death in glaucoma. Preventing these changes may halt cell death and loss of vision. Lamotrigine (used to treat epilepsy) is such an inhibitor. It will be tested in a rat glaucoma model to investigate its effect on the function and structure of the retina, and on molecular and genetic events in the ganglion cells. Positive results may lead to human testing.
Grants
Related Grants
National Glaucoma Research
The Role of Microtubules in Glaucomatous Schlemm’s Canal Mechanobiology
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Haiyan Li, PhD
The Role of Microtubules in Glaucomatous Schlemm’s Canal Mechanobiology
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Haiyan Li, PhD
National Glaucoma Research
Pressure-Induced Axon Damage and Its Link to Glaucoma-Related Vision Loss
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Bingrui Wang, PhD
Pressure-Induced Axon Damage and Its Link to Glaucoma-Related Vision Loss
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Bingrui Wang, PhD
National Glaucoma Research
Why Certain Retina Ganglion Cells Stay Strong in Glaucoma
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Mengya Zhao, PhD
Why Certain Retina Ganglion Cells Stay Strong in Glaucoma
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Mengya Zhao, PhD